糖皮质激素诱发骨质疏松研究进展  

Research progress on glucocorticoid induced osteoporosis

作　　者：罗文[1] 陈静[1] LUO Wen;CHEN Jing(Department of Clinical Pharmacy,the Third Hospital of Mianyang,Sichuan Mental Health Center,Mianyang 621000,Sichuan Province,China)

机构地区：[1]绵阳市第三人民医院,四川省精神卫生中心临床药学科,四川绵阳621000

出　　处：《世界临床药物》2024年第5期464-469,共6页World Clinical Drug

摘　　要：糖皮质激素(glucocorticoid,GC)被广泛用于炎症、免疫系统疾病的治疗,但长期、高剂量使用可引发多种药物相关不良反应,其中包括GC诱发的骨质疏松(glucocorticoid induced osteoporosis,GIO)。GC过量可对骨细胞产生有害影响,导致骨形成和骨吸收受损,故所有长期使用GC者需定期接受骨折风险评估。现总结GIO发病机制、临床表现、骨折风险和治疗策略,为临床提供一定参考。Glucocorticoid(GC)is widely used in the treatment of inflammation and immune system diseases,but long-term and high-dose use can cause various drug-related adverse reactions,including GC induced osteoporosis(GIO).Excessive GC can have harmful effects on bone cells,leading to impaired bone formation and resorption.Therefore,all long-term users of GC need to undergo regular fracture risk assessments.The article discussed the pathogenesis,clinical manifestations,fracture risk,and treatment strategies of GIO,to provide some reference for clinical practice.

关 键 词：糖皮质激素 骨质疏松 成骨细胞 破骨细胞 骨细胞 

分 类 号：R580[医药卫生—内分泌]